Coverage
-
March 24, 2014
A West Virginia federal judge ruled Friday that claims asserted by Mylan Inc. in a patent-infringement suit over Teva Pharmaceutical USA Inc.'s planned generic version of Mylan's respiratory illness drug Perforomist weren't invalid due to anticipation, obviousness or enablement.
1 other articles on this case.
View all »